tirzepatide우선순위 낮음근거 검토기타
LITERATURE DETAIL · PMID 42552238
GLP-1 Receptor Agonist Therapy for Obesity Under Japan's Optimal Use Guideline: A Prospective Real-World Study of Lifestyle Pre-Treatment, Time-Limited Treatment Cap, and Post-Cessation Regain.
GLP-1 Receptor Agonist Therapy for Obesity Under Japan's Optimal Use Guideline: A Prospective Real-World Study of Lifestyle Pre-Treatment, Time-Limited Treatment Cap, and Post-Cessation Regain.
- 저자
- Susumu Inamine, Yasunori Uesato
- 저널
- Diabetes, obesity & metabolism
- 공개일
- 2026 Aug 04
- 연구 유형
- 기타
- DOI
- 10.1111/dom.71190
문헌 요약
Japan's optimal use guideline restricts insurance-reimbursed GLP-1 receptor agonist (GLP-1 RA) therapy for obesity to patients completing a mandatory 6-month lifestyle intervention, caps treatment at 68 weeks (semaglutide 2.4 mg) or 72 weeks (tirzepatide), and mandates subsequent washout. We evaluated the clinical implications of this regulated program in…
PV 검토 포인트
누적 안전성 근거로 분류하고 기존 시그널과의 일관성을 확인합니다.